Atara Biotherapeutics Files Q1 2025 10-Q

Ticker: ATRA · Form: 10-Q · Filed: May 15, 2025 · CIK: 1604464

Atara Biotherapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type10-Q
Filed DateMay 15, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

Atara Bio's Q1 2025 10-Q is in. Check financials.

AI Summary

Atara Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities. Key financial data and operational updates are detailed within the filing, which covers the first quarter of 2025.

Why It Matters

This filing provides investors and stakeholders with the latest financial and operational performance of Atara Biotherapeutics, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — Biotechnology companies often face inherent risks related to drug development, regulatory approvals, and market competition, which are typically detailed in 10-Q filings.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, indicating the filing covers the period ending March 31, 2025.

When was this 10-Q filed with the SEC?

The filing date (FILED AS OF DATE) is 20250515.

What is Atara Biotherapeutics' primary business sector?

The Standard Industrial Classification code indicates the company is in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' [2836].

Where is Atara Biotherapeutics located?

The company's business and mailing address is 1280 Rancho Conejo Blvd, Thousand Oaks, CA 91320.

What is the SEC file number for Atara Biotherapeutics?

The SEC File Number is 001-36548.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing